KOD vs. LENZ, CRON, PRTA, AVBP, ORGO, CVAC, GHRS, NUVB, CRMD, and IMNM
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include LENZ Therapeutics (LENZ), Cronos Group (CRON), Prothena (PRTA), ArriVent BioPharma (AVBP), Organogenesis (ORGO), CureVac (CVAC), GH Research (GHRS), Nuvation Bio (NUVB), CorMedix (CRMD), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs.
Kodiak Sciences (NASDAQ:KOD) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, community ranking, analyst recommendations, media sentiment and institutional ownership.
LENZ Therapeutics' return on equity of -58.48% beat Kodiak Sciences' return on equity.
Kodiak Sciences received 7 more outperform votes than LENZ Therapeutics when rated by MarketBeat users. However, 100.00% of users gave LENZ Therapeutics an outperform vote while only 27.14% of users gave Kodiak Sciences an outperform vote.
In the previous week, Kodiak Sciences had 9 more articles in the media than LENZ Therapeutics. MarketBeat recorded 12 mentions for Kodiak Sciences and 3 mentions for LENZ Therapeutics. LENZ Therapeutics' average media sentiment score of 0.74 beat Kodiak Sciences' score of 0.66 indicating that LENZ Therapeutics is being referred to more favorably in the news media.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 38.4% of LENZ Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
LENZ Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Kodiak Sciences presently has a consensus target price of $9.00, indicating a potential upside of 306.87%. LENZ Therapeutics has a consensus target price of $41.67, indicating a potential upside of 96.91%. Given Kodiak Sciences' higher probable upside, research analysts plainly believe Kodiak Sciences is more favorable than LENZ Therapeutics.
Kodiak Sciences has a beta of 2.4, meaning that its share price is 140% more volatile than the S&P 500. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
Summary
Kodiak Sciences beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 4/4/2025 by MarketBeat.com Staff
Buy KOD Stock Free KOD Stock Alerts